– SEC Filing
On January 8, 2024, during its scheduled presentation at the 42nd Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter of 2023 is greater than $830 million including organic revenue growth greater than 12% year-over-year and that fourth quarter 2023 BSI bookings were solid. The Company also provided current preliminary expectation that revenue for the full year 2023 is greater than $2.94 billion, including organic revenue growth greater than 13% year-over-year. The Company also provided preliminary outlook for 2024 for solid, above-market growth in organic revenue, and non-GAAP EPS. A copy of the Company’s presentation is available in the “Investors” section of its website at ir.bruker.com.
Because the Company’s financial statements for the fourth quarter and fiscal year ended December 31, 2023 have not yet been finalized or audited, this preliminary statement regarding the Company’s current expectations with respect to its fourth quarter 2023 and full year 2023 revenue are subject to change, and the Company’s actual revenues for these periods may differ materially from these preliminary estimates. Accordingly, you should not place undue reliance on these preliminary estimates.
